ECUSTEC Newsletter

Issue 2 | April 2017

Full Title: Eculizumab in Shiga-toxin producing E.Coli Haemolytic Uraemic Syndrome (ECUSTEC): A Randomised, Double-Blind, Placebo-Controlled Trial

Short Title: The ECUSTEC trial

Welcome to the second issue of the ECUSTEC Newsletter!
We are hoping to start recruiting in Spring 2017!

Design:
Phase II randomised, parallel-group, double blind, placebo-controlled trial.

Aim:
To assess whether Eculizumab (Ecu) reduces the severity of Shiga-toxin producing Escherichia coli Haemolytic Uraemic Syndrome (STEC HUS) in children and young people.

Birmingham Clinical Trials Unit (BCTU) Easter Closure 2017

Please note that the ECUSTEC trial office at BCTU will be closed from:
5pm Thursday 13th April 2017 until 9am Thursday 20th 2017.

The ECUSTEC trial is supported by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR Partnership

ECUSTEC Progress Update!!!

The ECUSTEC trial received **MHRA approval** on the **3rd January 2017** and **REC approval** on the **23rd January 2017**. A substantial amendment is currently being submitted which will include changes to the protocol and will align the REC and MHRA approved versions. For further information about the protocol amendment and HRA approval please contact the trial coordinator (Emma Barsoum, barsoume@bham.ac.uk). The trial has been adopted onto the **Clinical Research Network (CRN) for Children portfolio** (reference: 32199).

Participating in ECUSTEC	The trial will take place in **12** centres across the UK with the assistance of the Clinical Research Network (CRN). Applications are currently in progress from **12** ECUSTEC sites to gain all the necessary NHS permissions to allow the trial to begin at each site. The table below shows the ECUSTEC sites that were included in the initial IRAS applications.

Alder Hey Children's Hospital	**Leeds General Infirmary**
Birmingham Children's Hospital	**Nottingham Children's Hospital**
Bristol Royal Hospital for Children	**Royal Hospital for Children, Glasgow**
Evelina London Children's Hospital	**Royal Manchester Children's Hospital**
Great North Children's Hospital	**Southampton Children's Hospital**
Great Ormond Street Hospital	**University Hospital of Wales**



ECUSTEC Trial Details

ECUSTEC is a randomised, parallel-group, double blind, placebo-controlled trial of eculizumab in 134 children aged 6 months to <19 years, inclusive, with STEC HUS. The trial contains an internal pilot phase of 18 months (12 months recruitment, 6 months follow up) to determine whether the substantive trial will continue.

Need for the ECUSTEC trial

The use of eculizumab for the treatment of severe STEC HUS is increasing internationally, with no objective evidence of efficacy or safety in children, and at huge cost to the NHS and other health services. If the efficacy of eculizumab in STEC HUS is not properly evaluated in a prospective trial, unregulated use will increase until a controlled trial becomes unfeasible. The ECUSTEC trial provides the opportunity to evaluate eculizumab in STEC HUS objectively. If efficacious, this treatment may alter the natural history of STEC HUS, reducing acute mortality, morbidity and long term sequelae. If eculizumab is found to be ineffective, the trial will help to ensure that NHS resources are not wasted.

Follow-up

All participants will be followed-up for 52 weeks. **Daily until discharge** (reducing to weekly after Day 14 if still admitted), then at **30 and 60 days** and then **6 and 12 months** post randomisation.

Notices to ECUSTEC Investigators

Site Initiation Visits

The trials team would like to thank all of the staff at ECUSTEC recruiting and patient identification centres (PICs) for your assistance during site set up. If you are a **recruiting centre** please contact the trials team (**ecustec@trials.bham.ac.uk**) to begin arranging **site initiation visits**.

Site Agreements

The twelve recruiting tertiary centres have now received the model non-commercial agreements. If your centre has any **outstanding queries** regarding site agreements please inform the trials team who will work with you to resolve any outstanding queries.

Site Files

Site and Pharmacy files will be provided by the trials team to recruiting sites and will contain all of the documentation you will need to run the trial at your site.

ECUSTEC Details:		
Trial Sponsor: The Newcastle Upon Tyne Hospitals NHS Foundation Trust **IRAS Project Code:** 199217		**Funding:** National Institute for Health Research Health, Efficacy and Mechanism Evaluation Programme (NIHR EME). **Ref: 14/48/43**
EUDRACT No: 2016-000997-39 **CTA**: 17136/0282/001-0001 Approval: 3rd January 2017	**REC Ref No.:** 16/NE/0325 North East - Newcastle & North Tyneside 1 Research Ethics Committee Approval: 23rd January 2017	**The ECUSTEC trial has been adopted by the NIHR Clinical Research Network (CRN)**

ECUSTEC Trial Schema



*Meningococcal B vaccine (Bexsero™) and conjugate meningococcal ACYW vaccine (Nimenrix or Menveo) will be given to all ECUSTEC trial participants (unless Bexsero™ already received as part of UK immunisation programme). Child <12 months Menveo; =12 months Menveo or Nimentrix. If platelet count $<50x10^9/l$ defer vaccination until platelet $>50x10^9/l$

** erythromycin if penicillin allergic

*** assessment at day 21 and 30 if in-patient

The EUCSTEC trial team are always here to help.

ECUSTEC Chief Investigator: Dr Sally Johnson, The Newcastle Upon Tyne Hos-	**Tel:** 0191 282 4917 **Email:** sally.johnson@nuth.nhs.uk
ECUSTEC WEBSITE: http://www.birmingham.ac.uk/ECUSTEC	**ECUSTEC FAX:** 0121 415 9135 **ECUSTEC Tel:** 0121 415 9132 **ECUSTEC Email**: ecustec@trials.bham.ac.uk

POSTAL ADDRESS: ECUSTEC Trial Office, Birmingham Clinical Trials Unit (BCTU), Institute of Applied Health Research, Public

Thank you for taking the time to read the ECUSTEC Newsletter. We would like to take this opportunity to wish you a very Happy Easter!!!